Catalent – Operational Inefficiencies, Potential Danaher Acquisition Implications & Manufacturing Modality Expansion

  • Public Equity
  • Healthcare
  • North America


Former executive at Catalent Inc


  • Detailing the CDMO (contract development and manufacturing organisation) environment surrounding Catalent (NYSE: CTLT), noting significant trends and developments
  • Catalent’s competitive positioning in the C&GT (cell and gene therapy) manufacturing space, highlighting relevant forms of differentiation
  • Service offering analysis, discussing mRNA production capabilities and introduction of UpTempo AAV (adeno-associated virus) platform for gene therapy development, alongside portfolio enhancement implications via Catalent’s commercial partnerships
  • Catalent’s technological integration into its various solutions and ability to conduct efficient tech transfers across multiple facilities
  • 12-18-month growth trajectory for Catalent, highlighting possible headwinds and tailwind scenarios


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited